<DOC>
	<DOCNO>NCT02471274</DOCNO>
	<brief_summary>To evaluate effect mild , moderate , severe hepatic impairment pharmacokinetics ( PK ) single dose 400 mg sotagliflozin ( 2 x 200-mg tablet ) compare healthy , demographically-matched subject .</brief_summary>
	<brief_title>PK Study Sotagliflozin Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Adult male female subject ≥18 ≤70 year age Body mass index ≥18.0 ≤36.0 kg/m2 , inclusive , Screening Subjects mild , moderate , severe hepatic impairment Control group match healthy subject Willing able provide write informed consent Presence clinically significant physical , laboratory , ECG finding may interfere aspect study conduct interpretation result Existence surgical medical condition might interfere absorption , distribution , metabolism , excretion sotagliflozin History major surgery within 6 month History renal disease , significantly abnormal kidney function test Women breastfeed plan become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>